Trellus Health
plc
("Trellus Health", the
"Company" or the "Group")
Change of Registered
Office
LONDON, U.K. AND NEW YORK, U.S. (27
December 2024). Trellus Health plc (AIM: TRLS),
a healthcare
company offering a digital platform and services
designed to deliver scientifically validated, personalised programs
and integrated value-based healthcare and pharma solutions for the
management of complex chronic conditions, announces today that its registered
office address, previously situated at Avon House, 19 Stanwell
Road, Penarth, Cardiff, United Kingdom, CF64 2EZ, has changed with
immediate effect to 201 Temple Chambers, 3 - 7 Temple Avenue,
London, England, EC4Y 0DT.
For further information
please contact:
|
Trellus Health plc
|
https://trellushealth.com/
|
|
Dr. Marla Dubinsky, Chief Executive
Officer and Co-Founder
|
Via Walbrook
PR
|
|
Joy Bessenger, Chief Financial
Officer
|
|
|
|
|
|
Singer Capital Markets (Nominated Adviser and
Broker)
|
Tel: +44 (0)20 7496
3000
|
|
Jen Boorer / James Todd / Jalini
Kalaravy
|
|
|
|
|
|
Walbrook PR
|
Tel: +44 (0)20 7933
8780 or trellus@walbrookpr.com
|
|
Paul McManus / Phillip Marriage
/
Louis Ashe-Jepson
|
Mob: +44
(0)7980 541 893 / +44 (0)7867 984 082 /
+44
(0)7747 515 393
|
|
|
| |
About Trellus Health plc (www.trellushealth.com)
Trellus Health (AIM: TRLS) is a
healthcare company providing value-based innovative solutions and
services, helping people with chronic conditions take control of
their health through a proven, scientifically validated
self-management solution and continuous, personalised support.
Trellus Health's approach empowers patients to better navigate the
emotional and physical challenges of their conditions, leading to
significant cost savings, enhanced treatment adherence, and
long-term, sustainable health outcomes.
Trellus Health integrates its
proprietary resilience-based methodology with the technology,
tools, and expert coaching and educator team to deliver Trellus
Elevate™, a whole-person technology-enhanced condition management
platform. The Company is initially focusing on chronic costly GI
conditions that have a high mental health burden, such as
Inflammatory Bowel Disease (IBD). Among IBD patients, applying
Trellus Elevate™ resulted in over 90% fewer hospitalisations and a
reduction of over 70% in emergency room visits. Given the common
emotional and mental health struggles associated with a variety of
chronic conditions, Trellus Health considers its approach to have
potential utility and demand across many conditions.
Trellus Health® also
offers a seamless solution for pharmaceutical partners from
clinical trials to commercialisation, harnessing resilience-based
methods to drive both trial and patient support success by
empowering patients to stay engaged, adhere to their treatment, and
manage their health confidently.
The Company was founded by Mount
Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD,
both world-leading experts at treating and healing both the
physical and emotional impacts of IBD and have been innovators for
whole-person healthcare for a combined 50 years.
Shares in Trellus Health were
admitted to trading on AIM in May 2021, under the ticker TRLS. For
more information, visit: www.trellushealth.com
